Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin From Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox) Using Focused Ultrasound in Patients With Primary or Secondary Liver Tumours

Trial Profile

A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin From Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox) Using Focused Ultrasound in Patients With Primary or Secondary Liver Tumours

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Cholangiocarcinoma; Liver cancer; Liver metastases
  • Focus First in man; Pharmacokinetics; Proof of concept
  • Acronyms TARDOX
  • Most Recent Events

    • 17 Jan 2019 Results presented in a Celsion Corporation media release.
    • 17 Jan 2019 According to a Celsion Corporation media release, the results from this study were published in the peer-reviewed journal, Radiology.
    • 10 Jul 2018 According to a Celsion Corporation media release, this trial is supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre and was carried as part of a multi-disciplinary collaboration between Celsion, the Oxford University Institute of Biomedical Engineering, the Oncology Clinical Trials Office (OCTO) and the Oxford University Hospitals NHS Foundation Trust.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top